Selective A2B Adenosine Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a continuing need for selective antagonists of the A2B adenosine receptors, as few compounds are known to effectively target this receptor subtype, which is implicated in various pathological conditions such as asthma, allergies, and diabetes.
Innovation Solution
Substituted 8-[6-amino-3-pyridyl]xanthines and their stereoisomers or pharmaceutically acceptable salts are developed to act as antagonists of A2B adenosine receptors, which can be used in pharmaceutical compositions to treat conditions associated with deleterious A2B receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If theophylline is used as a bronchodilator, then asthma treatment is achieved, but unpleasant side effects such as insomnia and diuresis occur
Solution Approach 1:
The patent applies local quality by creating selective A2B adenosine receptor antagonists that target a specific receptor subtype rather than acting as non-selective antagonists like theophylline. This selective targeting allows the drug to provide bronchodilation benefits while avoiding the harmful side effects caused by non-selective receptor blocking, thereby resolving the contradiction between treatment effectiveness and side effect profile
Solution Approach 2:
The patent changes the pharmacological parameter of receptor selectivity by developing compounds with high affinity and selectivity for A2B adenosine receptors. This parameter change from non-selective to selective receptor antagonism enables the maintenance of therapeutic effectiveness while eliminating the harmful side effects associated with theophylline's non-selective mechanism
2Object-generated harmful factors
If selective A2B adenosine receptor antagonists are developed, then side effects are reduced, but fewer compounds are known to effectively target this receptor subtype
Solution Approach 1:
The patent applies segmentation by systematically exploring and developing a series of related compounds with different structural modifications at the 8-position of the xanthine core. This segmentation approach allows for the optimization of binding affinity and selectivity for A2B receptors while maintaining a manageable scope of synthesis and characterization, thereby resolving the contradiction between reduced side effects and limited compound knowledge
Solution Approach 2:
The patent utilizes parameter changes by modifying molecular parameters such as substituent types, steric configurations, and electronic properties to optimize A2B receptor binding. These systematic parameter variations enable the development of multiple selective antagonists with improved profiles, addressing the limitation of few known compounds while maintaining reduced side effect characteristics
Data Source
AI summary
The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.